Vivesto AB (VIVE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vivesto AB (VIVE) has a cash flow conversion efficiency ratio of -0.039x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.46 Million ≈ $-695.20K USD) by net assets (Skr166.56 Million ≈ $17.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Vivesto AB market cap and net worth for the company's overall valuation and market capitalisation.
Vivesto AB - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Vivesto AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vivesto AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivesto AB ranked by their cash flow conversion efficiency. Explore how high is Vivesto AB's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ESV Inc
KQ:223310
|
-0.403x |
|
Techstep ASA
OL:TECH
|
0.098x |
|
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
|
-0.015x |
|
Healthcare Triangle Inc
NASDAQ:HCTI
|
-0.017x |
|
Rewardle Holdings Ltd
AU:RXH
|
-0.038x |
|
Emerge Commerce Ltd
V:ECOM
|
-0.121x |
|
Ben Tre Pharmaceutical JSC
VN:DBT
|
N/A |
|
Big Rock Brewery Inc.
TO:BR
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Vivesto AB (2004–2025)
The table below shows the annual cash flow conversion efficiency of Vivesto AB from 2004 to 2025. View latest Vivesto AB stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr124.58 Million ≈ $13.41 Million |
Skr-33.96 Million ≈ $-3.65 Million |
-0.273x | +8.64% |
| 2024-12-31 | Skr158.33 Million ≈ $17.04 Million |
Skr-47.25 Million ≈ $-5.08 Million |
-0.298x | +14.14% |
| 2023-12-31 | Skr197.80 Million ≈ $21.29 Million |
Skr-68.74 Million ≈ $-7.40 Million |
-0.348x | -40.46% |
| 2022-12-31 | Skr325.42 Million ≈ $35.02 Million |
Skr-80.52 Million ≈ $-8.66 Million |
-0.247x | +6.56% |
| 2021-12-31 | Skr549.71 Million ≈ $59.16 Million |
Skr-145.56 Million ≈ $-15.67 Million |
-0.265x | +11.23% |
| 2020-12-31 | Skr686.74 Million ≈ $73.90 Million |
Skr-204.86 Million ≈ $-22.05 Million |
-0.298x | -3460.04% |
| 2019-12-31 | Skr819.39 Million ≈ $88.18 Million |
Skr-6.87 Million ≈ $-738.89K |
-0.008x | +97.01% |
| 2018-12-31 | Skr424.05 Million ≈ $45.63 Million |
Skr-118.84 Million ≈ $-12.79 Million |
-0.280x | +21.79% |
| 2017-12-31 | Skr345.04 Million ≈ $37.13 Million |
Skr-123.63 Million ≈ $-13.30 Million |
-0.358x | +19.08% |
| 2016-12-31 | Skr300.37 Million ≈ $32.32 Million |
Skr-133.01 Million ≈ $-14.31 Million |
-0.443x | -12.69% |
| 2015-12-31 | Skr326.05 Million ≈ $35.09 Million |
Skr-128.13 Million ≈ $-13.79 Million |
-0.393x | -37.13% |
| 2014-12-31 | Skr375.71 Million ≈ $40.43 Million |
Skr-107.67 Million ≈ $-11.59 Million |
-0.287x | +7.04% |
| 2013-12-31 | Skr281.91 Million ≈ $30.34 Million |
Skr-86.90 Million ≈ $-9.35 Million |
-0.308x | -41.47% |
| 2012-12-31 | Skr319.15 Million ≈ $34.35 Million |
Skr-69.54 Million ≈ $-7.48 Million |
-0.218x | -13.63% |
| 2011-12-31 | Skr273.47 Million ≈ $29.43 Million |
Skr-52.44 Million ≈ $-5.64 Million |
-0.192x | +2.07% |
| 2010-12-31 | Skr294.17 Million ≈ $31.66 Million |
Skr-57.60 Million ≈ $-6.20 Million |
-0.196x | -147.13% |
| 2009-12-31 | Skr141.80 Million ≈ $15.26 Million |
Skr-11.23 Million ≈ $-1.21 Million |
-0.079x | -133.97% |
| 2008-12-31 | Skr61.21 Million ≈ $6.59 Million |
Skr14.28 Million ≈ $1.54 Million |
0.233x | +167864.83% |
| 2007-12-31 | Skr64.81 Million ≈ $6.97 Million |
Skr9.00K ≈ $968.54 |
0.000x | +100.07% |
| 2006-12-31 | Skr110.30 Million ≈ $11.87 Million |
Skr-22.73 Million ≈ $-2.45 Million |
-0.206x | -7.71% |
| 2005-12-31 | Skr58.90 Million ≈ $6.34 Million |
Skr-11.27 Million ≈ $-1.21 Million |
-0.191x | -192.02% |
| 2004-12-31 | Skr31.40 Million ≈ $3.38 Million |
Skr6.53 Million ≈ $702.68K |
0.208x | -- |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantri… Read more